QRFT2.440%
as of Jul 8
LLY
GrowthELI LILLY & CO
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer.
Close · 3M
+13.74%
Held by 4 AI ETFs
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals25
Win rate20% (5/25)
Avg buy return-3.29%
QRFT · Accumulation · 5d
The incremental increase in QRFT's LLY allocation, moving from 2.28% to 2.48% across a two-week period with minor daily adjustments, points to a sustained signal from the Qraft AI. This gradual accumulation occurs even as LLY trades at its 52-week high of $1235.56 after a 58.8% annual return, indicating the AI's weighting of the stock's strong momentum factor. Despite LLY's PER of 44.81 and PBR of 38.29, its 47.44% revenue growth and 101.31% return on equity likely contribute to a favorable quality assessment by the AI, which integrates these traditional factors with proprietary alternative data overlays. Such precise, nearly daily adjustments within QRFT's weekly rebalancing framework permit this broad large-cap core fund to incrementally increase exposure to a high-performing asset.
weight 2.280% → 2.480% (+0.200 pp)·stock up 9.8% in the 30 days before
Jul 7·entry $1235.56·now $1146.90Fresh
-7.18%
since Jul 7
QRFT · Accumulation · 5d
Eli Lilly's revenue growth of 47.44% and return on equity of 101.31% present a picture of considerable financial strength, aligning with the quality and momentum factors Qraft AI incorporates for its broad large-cap core QRFT fund, despite a PER of 44.81. This gradual accumulation, spanning late June into early July, unfolded as LLY was trading near its 52-week high of $1229.93, specifically at $1200.06, following a 15.2% gain over the preceding 30 days. The Qraft AI’s proprietary alternative-data overlays, combined with traditional factors, likely identified sustained positive signals within the stock, prompting QRFT to incrementally increase its weighting in LLY from 2.27% to 2.44% even at this elevated price level. This measured increase, reflecting LLY's strong financials and market performance, indicates the AI's algorithm found sufficient justification to add to the position.
weight 2.270% → 2.390% (+0.120 pp)·stock up 11.2% in the 30 days before
Jul 6·entry $1200.06·now $1146.90Fresh
-4.43%
since Jul 6
QRFT · Accumulation · 6d
Eli Lilly & Co's recent financial figures, including a 47.44% revenue growth and 101.31% return on equity, align with QRFT's AI-driven method, which integrates quality factors into its broad large-cap core strategy. This positive financial data likely signaled continued strength to the Qraft AI, prompting a gradual accumulation of the Health Care stock, with its weight increasing from 2.24% to 2.44% between June 23 and July 2. The Qraft AI's proprietary alternative-data overlays, combined with traditional factor analysis, appear to have supported these additions even as LLY traded at $1213.91, close to its 52-week high of $1229.93, after a 59.2% one-year return. Despite LLY's high price-to-earnings ratio of 44.81 and price-to-book ratio of 38.29, the system's assessment indicated sustained upside, justifying its presence as a component in QRFT's diversified portfolio of approximately 300 US large caps.
weight 2.240% → 2.440% (+0.200 pp)·stock up 14.1% in the 30 days before
Jul 2·entry $1213.91·now $1146.90Fresh
-5.52%
since Jul 2
QRFT · Accumulation · 6d
QRFT's AI-driven approach, which integrates traditional factors like momentum and quality with proprietary alternative data overlays, appears to have identified sustained positive signals in Eli Lilly. Given its weekly rebalancing schedule and management of around 300 US large-cap positions, the AI system incrementally increased LLY's allocation from 2.1800% to 2.3900% over the specified period. This steady build-up in weighting suggests the AI prioritized the company's strong financial momentum, evidenced by its 47.44% revenue growth, alongside other proprietary data insights. Operating as a broad large-cap core fund with an AI tilt, QRFT likely recognized Eli Lilly's current market strength, trading at 99% of its 52-week high, as a compelling position for accumulation within its diversified strategy.
weight 2.180% → 2.390% (+0.210 pp)·stock up 10.1% in the 30 days before
Jul 1·entry $1191.74·now $1146.90Fresh
-3.76%
since Jul 1
QRFT · Accumulation · 5d
Eli Lilly shares trade near their 52-week high of $1229.93, with the current price of $1199.43 reflecting a 98% position relative to that peak and a 30-day return of +21.4%. This strong price momentum, alongside the company's 47.44% revenue growth and a 101.31% return on equity, likely signaled to Qraft AI a compelling growth story despite its high PER of 42.05 and PBR of 38.29. Qraft’s AI, which integrates momentum and quality factors with proprietary alternative data, appears to have identified sustained strength in LLY, aligning with its broad large-cap core mandate. The fund’s weekly rebalancing mechanism, combined with the AI’s detection of LLY’s sustained attributes, led to a phased increase in its allocation from 2.1800% to 2.4700% over several days in late June. This strategy underscores QRFT's AI-tilt, allowing for measured position sizing in high-growth, high-valuation stocks showing consistent performance trends.
weight 2.180% → 2.380% (+0.200 pp)·stock up 8.5% in the 30 days before
Jun 30·entry $1199.43·now $1146.90Fresh
-4.38%
since Jun 30
QRFT · Accumulation · 5d
QRFT, which employs an AI combining traditional factors and proprietary alternative-data overlays across its portfolio of approximately 300 US large caps, demonstrated a deliberate increase in its LLY weighting. This reflects the fund's specific methodology, which includes a weekly rebalancing cadence, identifying opportunities for sustained exposure rather than quick trades. The AI's analysis, informed by both fundamental metrics and alternative data, likely identified LLY as a compelling holding, despite its high valuation. Such a sustained accumulation, peaking at 2.47% from an initial 2.23% within a single rebalance cycle, indicates the system's conviction, even as LLY trades at $1229.93, precisely at its 52-week high. This conviction is further supported by LLY's reported 47.44% revenue growth and 101.31% ROE, figures that likely flagged the stock as a strong candidate for continued weighting within QRFT's broad large-cap core mandate.
weight 2.230% → 2.470% (+0.240 pp)·stock up 9.2% in the 30 days before
Jun 29·entry $1229.93·now $1146.90Fresh
-6.75%
since Jun 29
QRFT · Weight increase · 4d
stock up 11.6% in the 30 days before
Jun 26·entry $1208.12·now $1146.90Fresh
-5.07%
since Jun 26
QRFT · Weight increase · 3d
stock up 5.9% in the 30 days before
Jun 25·entry $1127.69·now $1146.90Fresh
+1.70%
since Jun 25
PQUS · Weight increase · 3d
LLY's financial profile, featuring a 47.44% revenue growth and 101.31% return on equity, points to the underlying performance characteristics favored by Pictet Asset Management's AI ranking system for the PQUS ETF. These metrics indicate a company demonstrating significant financial strength within the US large-cap universe, aligning with the fund's style. Operating within a strategy of measured turnover for its ~165 US large caps, the AI system for PQUS detected favorable conditions for LLY, which trades near 95% of its 52-week high after delivering a 52.6% one-year return. Following a minor reduction on July 16, the consecutive weight increases from 2.04% to 2.12% between July 17 and July 19, 2026, suggest the AI system’s periodic rebalance prioritized LLY due to its sustained price momentum and strong underlying financials, while adhering to the ETF's sector-balance and concentration rules.
weight 1.920% → 2.120% (+0.200 pp)·stock up 5.0% in the 30 days before
Jul 19·entry $1146.90·now $1146.90Fresh
0.00%
since Jul 19
PQUS · Weight increase · 2d
Pictet Asset Management's PQUS, leveraging its AI ranking system across ~165 US large caps, initiated a measured increase in LLY's weighting, moving from 2.04% to 2.07% over two consecutive days. This specific adjustment reflects the AI's re-evaluation of LLY, incorporating new data points during a periodic rebalance cycle rather than daily adjustments. The AI's model likely identified LLY's sustained operational strength, evidenced by its reported 101.31% Return on Equity, making it a compelling candidate for allocation within the fund's sector-balanced framework. Despite LLY's current price sitting at 95% of its 52-week high, the AI system continued to incrementally increase its position, indicating sustained positive signal strength for the pharmaceutical giant.
weight 1.920% → 2.070% (+0.150 pp)·stock up 5.0% in the 30 days before
Jul 18·entry $1146.90·now $1146.90Fresh
0.00%
since Jul 18
PQUS · Weight decrease · 2d
Pictet Asset Management's PQUS, which manages approximately 165 US large caps using an AI ranking system, has systematically reduced its LLY allocation. This periodic rebalancing suggests the AI algorithm is adjusting positions in response to the stock's valuation metrics and recent price appreciation. Despite LLY's 47.44% revenue growth, its current price, now at 96% of its 52-week high, may have prompted the AI to decrease its weight from 2.05% to 1.98% in recent days. Such adjustments align with the fund's sector-balance and concentration rules, ensuring the portfolio adheres to its measured turnover style while moderating exposure to a security that has seen a significant +53.3% 1-year return.
weight 2.050% → 1.980% (-0.070 pp)·stock up 3.8% in the 30 days before
Jul 12·entry $1181.87·now $1146.90
-2.96%
since Jul 12
PQUS · Accumulation · 5d
Pictet Asset Management's AI ranking system, applied across its ~165 US large-cap holdings, likely signaled Eli Lilly's compelling attributes for gradual accumulation. The system, balancing sector exposure and concentration, identified LLY’s 47.44% revenue growth as a significant factor. Consequently, PQUS implemented a measured increase in its LLY position, moving from 1.81% to 2.13% between June 24th and July 1st. This gradual accumulation, characteristic of the fund’s periodic rebalancing and measured turnover style, occurred even as LLY traded at $1199.43, close to its 52-week high.
weight 1.810% → 2.130% (+0.320 pp)·stock up 10.1% in the 30 days before
Jul 1·entry $1191.74·now $1146.90Fresh
-3.76%
since Jul 1
PQUS · Accumulation · 5d
PQUS's AI ranking system, applied to US large-caps, likely identified Eli Lilly & Co's (LLY) compelling 47.44% revenue growth and 101.31% ROE as primary drivers, favoring the stock despite its 42.05 P/E ratio and 38.29 P/B ratio. This positive algorithmic assessment prompted a gradual accumulation from 1.8000% to 2.0400% between June 23rd and June 28th, 2026, even as LLY traded at $1229.93, marking its 52-week high following a 30-day return of +22.4%. The measured turnover style of the newer fund, launched in 2025, along with its layered sector-balance and concentration rules, guided this measured increase, preventing an abrupt portfolio shift while still reflecting the AI's conviction in the stock's performance trajectory.
weight 1.800% → 2.040% (+0.240 pp)·stock up 8.5% in the 30 days before
Jun 30·entry $1199.43·now $1146.90Fresh
-4.38%
since Jun 30
PQUS · Accumulation · 5d
Pictet Asset Management’s AI ranking system, applied to its ~165 US large-cap holdings within PQUS, appears to have identified compelling fundamentals in LLY, driving its gradual accumulation. Despite the stock trading at 100% of its 52-week high, the AI's re-evaluation likely weighed LLY's significant revenue growth of 47.44% and a 1-year return of 47.4% as key drivers. The observed week-long increase from 1.8000% to 2.0400% aligns with the fund’s periodic, not daily, rebalancing cadence and its layered sector-balance and concentration rules, which temper position sizing. This strategic increase reflects the AI system's quantitative assessment of the company's strong financial performance, even as its P/E ratio stands at 42.05.
weight 1.800% → 2.040% (+0.240 pp)·stock up 9.2% in the 30 days before
Jun 29·entry $1229.93·now $1146.90Fresh
-6.75%
since Jun 29
PQUS · Accumulation · 5d
Eli Lilly (LLY) currently trades at $1208.12, reaching 100% of its 52-week high and delivering a 30-day return of +20.0%, indicating significant recent price appreciation. Despite this heightened valuation, with a PER of 42.05 and a PBR of 38.29, PQUS's AI ranking system likely identified the stock's strong fundamentals, including 47.44% revenue growth and a 101.31% return on equity, as key drivers. The AI's measured turnover approach, characteristic of this newer fund, resulted in a gradual accumulation of LLY shares, increasing its weight from 1.8000% to 2.0400% over the week of June 21-28, 2026. This systematic, multi-day increase aligns with the ETF's periodic rebalancing and concentration rules, integrating the high-performing large-cap into its portfolio despite its elevated market price.
weight 1.800% → 2.040% (+0.240 pp)·stock up 11.6% in the 30 days before
Jun 28·entry $1229.93·now $1146.90Fresh
-6.75%
since Jun 28
PQUS · Weight increase · 4d
stock up 11.6% in the 30 days before
Jun 27·entry $1229.93·now $1146.90Fresh
-6.75%
since Jun 27
PQUS · Weight increase · 3d
stock up 11.6% in the 30 days before
Jun 26·entry $1208.12·now $1146.90Fresh
-5.07%
since Jun 26
PQUS · Weight increase · 2d
stock up 5.9% in the 30 days before
Jun 25·entry $1127.69·now $1146.90Fresh
+1.70%
since Jun 25
AIEQ · Weight increase · 2d
AIEQ's IBM Watson NLP engine, which analyzes diverse data like news, filings, and social posts across thousands of US equities, consistently generated favorable signals for Eli Lilly, resulting in its consecutive weight increase. The fund’s daily rebalancing and high turnover among its 140-180 US stocks mean such a sustained allocation shift reflects a continuous top-tier ranking by the AI. This consistent positive sentiment, part of the fund's fundamentals plus sentiment hybrid style, likely integrated LLY's 47.44% revenue growth alongside its recent price appreciation, which places it at 95% of its 52-week high. AIEQ’s system, managed by EquBot, is thus expressing continued conviction in LLY at the current $1179.11 price level.
weight 0.880% → 0.910% (+0.030 pp)·stock up 5.0% in the 30 days before
Jul 19·entry $1146.90·now $1146.90Fresh
0.00%
since Jul 19
AIEQ · Weight decrease · 2d
AIEQ's method, leveraging IBM Watson NLP across thousands of US equities for daily rankings, provides insight into the observed consecutive weight decrease for LLY. Operating a 140-180 stock portfolio with daily rebalancing, this broad market fund rapidly adjusts to shifts in information. Despite LLY's strong revenue growth of 47.44%, the AI's sentiment-hybrid approach may have detected subtle negative shifts or concerns around the company's valuation, especially with the stock currently trading at 96% of its 52-week high. This dynamic adjustment reflects EquBot's risk overlay converting daily AI output into precise position sizing.
weight 0.950% → 0.910% (-0.040 pp)·stock up 3.8% in the 30 days before
Jul 11·entry $1181.87·now $1146.90
-2.96%
since Jul 11
AIEQ · Sudden change · 1d
AIEQ's strategy, which relies on daily rebalancing derived from IBM Watson NLP's continuous analysis of thousands of US equities, likely detected a shift in sentiment or fundamental indicators for Eli Lilly & Co. The system's broad market approach, balancing fundamentals and sentiment, had seen LLY’s weight grow steadily, possibly driven by its significant 47.44% revenue growth. However, given LLY's current price near 97% of its 52-week high, new data ingested by the NLP model could have prompted EquBot's risk overlay to reduce exposure to the Health Care stock, leading to the sharp reduction on July 1st. This agile response aligns with the fund's highest-turnover characteristic among AI ETFs.
weight 1.250% → 0.930% (-0.320 pp)·stock up 10.1% in the 30 days before
Jul 1·entry $1191.74·now $1146.90
-3.76%
since Jul 1
AIEQ · Accumulation · 5d
LLY's financial profile, featuring a 47.44% revenue growth and 101.31% return on equity, aligns well with AIEQ's fundamental-driven selection criteria as part of its broad market strategy. While sporting a PER of 42.05 and PBR of 38.29, these growth metrics, alongside continually positive sentiment signals gathered by IBM Watson NLP from news and social posts, likely fueled the AI's interest. The gradual accumulation from June 21st to June 30th occurred precisely as LLY approached its 52-week high of $1229.93, indicating the AI system identified sustained positive catalysts. Given AIEQ's daily rebalancing and high-turnover nature, this sustained buying, even with a 30-day return of +21.4%, reflects the system's ongoing confidence in LLY's momentum based on its continuous data ingestion.
weight 1.110% → 1.250% (+0.140 pp)·stock up 8.5% in the 30 days before
Jun 30·entry $1199.43·now $1146.90Fresh
-4.38%
since Jun 30
AIEQ · Weight increase · 4d
Amplify's AIEQ, leveraging IBM Watson's NLP for daily sentiment and fundamental analysis, has shown a clear conviction in Eli Lilly & Co (LLY) by increasing its portfolio weighting across several trading days. This fund's high-turnover nature and daily rebalancing mechanism facilitate such rapid adjustments, evidenced by the progression from 1.11% to 1.24% between June 21st and June 28th. The AI's model, ingesting a broad spectrum of data from news to social posts, likely identified strong positive signals for LLY, which currently trades at its 52-week high of $1208.12. This sentiment is reinforced by LLY's financial performance, notably a 101.31% Return on Equity, aligning with AIEQ's broad market, fundamentals-plus-sentiment hybrid style. Such a pattern indicates the system detected persistent positive momentum and underlying financial strength within the health care sector.
weight 1.110% → 1.240% (+0.130 pp)·stock up 11.6% in the 30 days before
Jun 28·entry $1229.93·now $1146.90Fresh
-6.75%
since Jun 28
AIEQ · Weight increase · 3d
stock up 11.6% in the 30 days before
Jun 26·entry $1208.12·now $1146.90Fresh
-5.07%
since Jun 26
AIEQ · Weight increase · 2d
stock up 5.9% in the 30 days before
Jun 25·entry $1127.69·now $1146.90Fresh
+1.70%
since Jun 25
BUZZ · Weight decrease · 2d
ELI LILLY & CO, exhibiting a PER of 44.26, a PBR of 38.29, revenue growth of 47.44%, and an ROE of 101.31%, reflects a company with significant recent expansion and high market valuation. This strong performance is central to how BUZZ, a sentiment-tracking ETF utilizing NLP on social media and news, assesses stocks, as it captures the public's perception of such metrics rather than direct financial analysis. Despite these figures, the observed consecutive weight decrease in BUZZ from 0.37% to 0.35% between July 7th and July 9th suggests a softening in the positive-sentiment intensity for LLY within the ETF's tracked data sources. This subtle reduction in sentiment occurred while LLY was trading near its 52-week high of $1235.56, specifically at $1188.58, indicating the algorithmic tracker detected a marginal shift as the stock approached its peak valuation following a 5.5% 30-day return.
weight 0.370% → 0.350% (-0.020 pp)·stock up 5.9% in the 30 days before
Jul 9·entry $1216.95·now $1146.90
-5.76%
since Jul 9
BUZZ · Weight increase · 4d
stock up 11.6% in the 30 days before
Jun 26·entry $1208.12·now $1146.90Fresh
-5.07%
since Jun 26
BUZZ · Weight increase · 3d
stock up 5.9% in the 30 days before
Jun 25·entry $1127.69·now $1146.90Fresh
+1.70%
since Jun 25
BUZZ · Weight increase · 2d
stock up 4.9% in the 30 days before
Jun 24·entry $1117.26·now $1146.90Drifting
+2.65%
since Jun 24
LQAI · Exit · 1d
LLY exhibited a high PER of 44.81 and a PBR of 38.29, alongside 47.44% revenue growth and a 101.31% return on equity. These figures initially aligned with LQAI's AI-driven selection for US large-cap core names, which balances broad market appeal with elements of momentum without a heavy factor tilt. However, the Qraft AI ranking engine, which rebalances LQAI's ~100 US large-cap portfolio weekly, completely removed LLY on 2026-07-07. This action followed LLY reaching $1235.56, precisely its 52-week high, having gained 16.0% in the preceding 30 days. The AI likely determined the stock's current valuation, relative to its peak price and rapid short-term appreciation, no longer met its specific criteria for optimal core large-cap exposure within its weekly rebalance cycle.
weight 0.210% → 0 (exited)·stock up 9.8% in the 30 days before
Jul 7·entry $1235.56·now $1146.90
-7.18%
since Jul 7
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of Jul 19
The framework analysis concludes a 'Fail' due to the lack of a margin of safety at the current price, despite the company's strong fundamentals and moat. This contrasts with several AI ETFs (AIEQ, PQUS, QRFT) that have shown recent 'weight increase trends' or 'gradual accumulation,' suggesting they are buying into LLY's current valuation. Conversely, BUZZ has decreased its weight and LQAI has exited, aligning more with the caution on valuation.
- Circle of CompetenceThe underlying business model of a diversified pharmaceutical company like Eli Lilly, with established blockbusters and a robust pipeline, allows for reasonable long-term cash flow projections despite scientific complexity.
- Economic MoatEli Lilly benefits from robust patent protection on its key drugs, significant R&D capabilities, and strong brand recognition in critical therapeutic areas, creating a durable economic moat.
- ManagementWithout specific information on management's communication style, capital allocation decisions, and insider ownership, it is not possible to fully assess their alignment with the framework's criteria.
- Financial HealthWhile the reported ROE of over 100% is exceptionally strong, a complete assessment of financial health requires a 10-year ROE average, operating margin trends, and detailed debt analysis, which are not provided.
- Margin of SafetyThe current valuation multiples (PER 43.93, PBR 38.29, EV/EBITDA 110.78) are exceptionally high, leaving no defensible margin of safety relative to a conservative estimate of intrinsic value.
Eli Lilly is a robust pharmaceutical company operating within a predictable business model and possessing strong patent-driven moats. While its financial health appears exceptional with very high recent ROE, a complete assessment of management and the full financial picture is limited by available data. Crucially, the current market valuation indicates an extremely high price, which, from a value investing perspective, eliminates any margin of safety, leading to a 'Fail' verdict.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.